HI
COGT icon

HBK Investments’s Cogent Biosciences COGT Stock Holding History

HBK Investments’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,000
Closed -$1.78M – 1039
2018
Q1 		$1.78M Buy
+40,000
New +$1.78M 0.01% 483

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HBK Investments's COGT Position: Q2 2018 in Review

HBK Investments sold out of Cogent Biosciences (COGT) in Q2 2018, closing a stake of 40,000 shares — an estimated $1.78M sold.

HBK Investments first reported a position in COGT in Q1 2018 and held it in 1 quarter. The position peaked at $1.78M in Q1 2018. 44 funds tracked by Wall St. Rank hold COGT as of Q2 2018.

  • HBK Investments reported no remaining Cogent Biosciences position as of Q2 2018 after selling out during the quarter.
  • HBK Investments sold 40,000 Cogent Biosciences shares in Q2 2018, an estimated $1.78M.
  • HBK Investments first reported a position in Cogent Biosciences in Q1 2018 and held it in 1 quarter.
  • HBK Investments's Cogent Biosciences position peaked at $1.78M in Q1 2018.
  • 44 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2018.

Based on HBK Investments's 13F filing for Q2 2018, filed 14 Aug 2018.